Opendata, web and dolomites

Droplet Microarray SIGNED

Miniaturized System for Screening of Primary Cells based on Droplet Microarray

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 Droplet Microarray project word cloud

Explore the words cloud of the Droplet Microarray project. It provides you a very rough idea of what is the project "Droplet Microarray" about.

dispenser    therapeutic    disruptive    animal    model    consumption    stem    cartridge    slides    cell    hardly    nano    tests    integrates    miniaturization    generate    clinical    optimal    performing    discovery    larger    tumor    basic    clinicians    human    capturing    assays    labcyte    selling    medical    current    precious    science    patient    maximized    alternative    dispendix    extremely    models    direct    incubator    167m    liquid    apparatus    medicine    biological    drug    cells    nanoliter    screening    innovation    context    dma    revenues    screenings    37    scarcity    ec    life    experiments    relevance    market    sales    microtiter    b2b    healthy    precision    primary    microplates    2025    throughput    physiology    read    society    reagents    circulating    technologies    individual    therapies    replacing    plates    aquarray    reduce    limits    impossible    types    mass    inevitably    treatment    possibility    scarce    dispensers    mainly    personalized    business    companies    time    perform    employ   

Project "Droplet Microarray" data sheet

The following table provides information about the project.

Coordinator
AQUARRAY GMBH 

Organization address
address: HERMANN-VON-HELMHOLTZ-PLATZ 1
city: EGGENSTEIN-LEOPOLDSHAFEN
postcode: 76344
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 2˙499˙750 €
 EC max contribution 1˙749˙825 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2020
 Duration (year-month-day) from 2020-02-01   to  2022-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    AQUARRAY GMBH DE (EGGENSTEIN-LEOPOLDSHAFEN) coordinator 1˙749˙825.00

Map

 Project objective

Current cell screening systems based on microtiter plates are mainly used to perform drug discovery experiments. However, performing a larger number of therapeutic tests on patient derived (primary) cells is yet impossible due to the high consumption of reagents and cells when using microplates. In the clinical context, personalized drug screenings for optimal medical treatment are not possible due to the scarcity of precious primary cells. In pre-clinical drug discovery, the extremely high cost of primary cells limits the innovation potential as researchers hardly have access to screening models which are relevant for human physiology. The possibility to use scarce cell types like primary cells or stem cells therefore is the future of basic life science research, drug discovery (replacing animal models) as well as personalized medicine applications (individual precision therapies) and will have significant impact for a healthy society. Further miniaturization of current assays would inevitably allow the wide use of scarce cell types and at the same time reduce costs, increase throughput, and increase biological relevance of screening results. DMA allows researchers and clinicians to perform meaningful experiments with primary cells and circulating tumor cells – alternative technologies hardly work with low cell numbers. EC funding Phase 2 will allow Aquarray to mass produce its offer – the DMA Cartridge and also the disruptive Cell Screening System that integrates the DMA Cartridge with a nanoliter dispenser, an incubator and a read-out apparatus. Aquarray’s disruptive business model will employ a B2B direct sales of the DMA Slides and the Screening System, and at the same time sales can be maximized through partnerships with companies selling liquid nano-dispensers such as Dispendix and Labcyte. We are expected to generate €167M revenues by 2025 capturing 9.37% of the market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DROPLET MICROARRAY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DROPLET MICROARRAY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

IMPACT (2019)

Improving DNA Analysis for Correct Healthcare

Read More  

TankSensor (2020)

Smart monitoring solution for better procurement and supply chain management - Speeding up chemical industry digitalization

Read More  

CyreenApplication (2019)

Connecting Ad-Impressions with Purchase. The new advanced Advertisement at the point of sales.

Read More